younger median age (29 v 38 years); a prevalence of males (90% v 56%); and a higher percentage of stage IV disease (52% v 15%), presence of B symptoms (77% v 35%), and extranodal disease (63% v 29%). The complete remission (CR) rate (58%) and median survival (13 months) of patients treated prospectively were similar to that of patients treated with standard CT regimens. The statistically significant favorable prognostic factors for survival being the following: achievement of CR, CD4+ count greater than 250/4L, and no prior diagnosis of AIDS at onset of HD.
Conclusion: Our virologic findings indicate that HIVrelated HD is more closely associated with EBV than HD in the general population. The peculiar clinicopathologic findings, the role of some prognostic factors, and the possibility of cure of HIV-related HD have been demonstrated.
J Clin Oncol 13:1758-1767. O 1995 by American Society of Clinical Oncology.
significantly increased: HD and carcinomas of the anorectum. The excess of HD in this population-based cohort of patients with AIDS gives very strong support to previous reports, 5 "" which raised the possibility that at least a subset of HD may be part of the AIDS presentation. In fact, the findings of recent studies have documented a significant difference in the distribution of mixed cellularity (MC) and lymphocyte depletion (LD) subtypes of HD in HIV-infected patients compared with HD in the general population...4 Accordingly, HD has been described in patients with HIV infection in association with unfavorable prognostic factors such as advanced stage at presentation, unfavorable histologic subtypes, and aggressive clinical course.
•" ' The biologic basis and the molecular genetics underlying the pathogenesis of HD are still unclear. However, a pathogenetic role of Epstein-Barr Virus (EBV) in a large proportion of HD occurring in an HIV setting has been supposed on the basis of the highest frequency of EBV genome demonstration. 2 
-

PATIENTS AND METHODS
Patients and Case Selection
The GICAT was established in November 1986, with the aim of assessing the prevalence and outcome of malignant tumors in an HIV setting in Italy. A questionnaire was initially sent to the members of the Italian Society for Medical Oncology, Hematology, and Immunology, and to selected infectious disease specialists. Participating investigators were asked to identify all known patients at risk for AIDS in whom a malignant tumor had developed since November 1986. For the purposes of this study, a subsequent and specifically integrated form was sent to the investigators who had previously reported, or who were willing to report, cases of HD to the secretarial office of the GICAT. This form asked for data regarding the initial localization, histologic subtypes, clinical stages, treatment response, toxicity, causes of death, and survival.
The present study is based on a total of 114 patients with HD who were referred to the secretarial office of the GICAT from November 1986 to March 1994, and treated in 39 different Italian centers. An evaluation was performed on the basis of the data collected through the questionnaires and through case-by-case discussion with the physicians responsible for each patient. The majority of these patients were treated according to the individual center policy; however, since March 1989, a prospective study was undertaken, and a common clinical protocol was used in these patients. Individual pathologists at each individual hospital reviewed their own material.
To have a comparison group of patients with HD and without HIV infection, a series of 104 assessable patients who were histologically diagnosed, clinically evaluated, and treated at the Centro di Riferimento Oncologico of Aviano, Italy, between 1984 and 1991 was identified. These patients were part of a case-control study on risk factors for HD in northeast Italy." The reason for such a monoinstitutional series of HD in the general population was the fact that a significant proportion (22%) of cases with HIV infection collected by the GICAT was initially diagnosed, or histologically classified after review, by one of the authors (A.C.) at the Pathology Division of the Centro di Riferimento Oncologico (CRO), a comprehensive Cancer Center where the GICAT was established.
The subset of GICAT cases studied for EBV by immunohistochemistry, in situ hybridization, and molecular analyses was retrieved from the files of the Division of Pathology at the CRO. Among these cases, the number of LD-subtype HD investigated was relatively large. In this regard, it is worth noting that the majority of patients with HD and HIV infection has been specifically referred to CRO from other Italian regions. In particular, a number of cases with difficult diagnostic problems (anaplastic carcinomas or undifferentiated neoplasias v Hodgkin's or non-Hodgkin's lymphomas) have been referred. Among them, a nonnegligible number of HD cases of the LD subtype were diagnosed.
Pathologic Analysis
The Rye modification of the Lukes and Butler classification was used to classify HD." Distinct nodule and collagen band formation was required for diagnosing nodular sclerosing (NS) subtype, whereas lymph node biopsy specimens characterized by increased fibrohistiocytoid stromal cells arranged in bundles were classified as MC subtype." 0 Tumors were classified as LD subtype in the presence of diagnostic features for either "diffuse fibrosis" or "reticular" subtype. 
Immunohistochemistry With Anti-LMP-1
Immunohistochemical detection of EBV-encoded latent membrane protein-1 (LMP-1) was used for identifying EBV-associated HD occurring in patients with (18 cases) or without (104 cases) HIV infection. Anti-LMP-1 was available as a pool of four anti-LMP MAbs (CS 1-4) (Dakopatts, Glostrup, Denmark). Immunostaining was performed on Bouin-fixed or formalin-fixed, paraffin-embedded tissue sections by the alkaline phosphatase anti-alkaline phosphatase (APAAP) method. Positive controls were included in all test runs and consisted of sections of LMP-1-expressing EBV-positive cell lines. Negative controls consisted of consecutive test sections in which primary antibody was replaced by nonimmune serum of the same immunoglobulin (Ig) G subclass (Dakopatts).
In Situ Hybridization Studies
EBV-encoded RNAs in situ hybridization (EBERs ISH) studies were conducted on Bouin-fixed, paraffin-embedded tissue sections from 10 HD cases occurring in HIV-positive patients. A cocktail of fluorescein isothiocyanate (FITC)-labeled oligonucleotides complementary to the two nuclear EBER (1/2) RNAs encoded by EBV was used according to the instructions of the supplier (Dako A/S, Glostrup, Denmark), with minor modifications. Briefly, after deparaffinization, the slides were treated with I to 3 Mg/mL Proteinase K (Sigma Chemical Co, St Louis, MO), dehydrated in alcohol, air dried and incubated (2 hours at 37-C) with 10 to 15 MLL hybridization buffer that contained EBER (1/2 probes). After washings in tris buffered saline/0.1% triton x 100, slides were treated with 100 ig/mL RNase A (Boehringer, Mannheim, Germany) in 2 x saline sodium citrate buffer for 1 hour. Hybridization products were detected using an anti-FITC polyclonal antibody alkaline phosphatase conjugate (Dako A/S). After 5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium was used as chromogen, slides were counterstained with nuclear fast red, dehydrated, and mounted with a permanent mounting medium. The specificity of RNA signals was ascertained by abolition of hybridization after pretreatment of sections with RNase A.
Genotypic and Virologic Analysis
Ten HIV-associated and 20 HIV-unrelated HD cases were investigated for the presence of B-and T-cell clonal expansions. The configuration of EBV genome termini was analyzed in DNA of 10 HDs from HIV-infected patients and in 44 HD cases from the general population. Genomic DNA was extracted from frozen tissues according to conventional methods. Ten or 20 Mg of DNA were digested with the appropriate restriction enzymes. Size fractionation of DNA fragments, Southern blotting, molecular hybridization, and autoradiography were performed as described.' The following probes were used: the 3.1-kb BamHI-W fragment of B95-8 EBV strain specific for the large internal repeat the virus"; the 1.9-kb Xhol fragment corresponding to the EcoRI D fragment adjacent to EBV right terminal repeats," and the 4.1-kb EcoRI fragment corresponding to the EcoRI I region adjacent to EBV left terminal repeats to analyze the molecular conformation of the EBV genome; the 2.5-kb EcoRI fragment of Ig heavy-chain gene specific to the IgH region" 3 ; the 0.6-kb Sac I fragment specific to the Jk region'; the 8.0-kb EcoRI fragment of IgX light chain specific to the Ck region"; and the 0.6-kb HindlII-EcoRI fragment of TCRfl chain specific to the C6 region.' DNA from 10 HIV-associated and 20 HIV-unrelated HD cases was investigated by polymerase chain reaction (PCR) for the pres-ence of functional clonal V-D-J IgH gene rearrangements (VDJ PCR). The analysis was performed in triplicate using two different seminested PCR protocols, as described by Diss et al," with minor modifications." The characterization of the EBV subtypes was accomplished in 11 HIV-associated and 26 HIV-unrelated HD cases by a PCR amplification of the EBNA-2 region using primers specific for type I and type 2 EBV. A common 5' primer 5'-AGGGATGCC-TGGACAAGA-3', a type 1-specific 3' primer 5'-'I7GTGACAG-AGGTGACAAAA-3' and a type 2-specific 3' primer 5'-TTGAAG-AGTATGTCCTAAGG-3' were used to amplify products of 249 and 300 base pair, respectively. The amplification was preceeded by an initial denaturation step at 95'C for 7 minutes and followed by a primer extension step at 72'C for 10 minutes. One microgram of genomic DNA, in a reaction mixture as described by Saiki et al, 39 was subjected to 10 1-minute cycles at 94'C, 2 minutes at 55°C, and 1 minute at 70°C followed by 40 1-minute cycles at 90'C, 1I minute at 550C, and 1 minute at 70"C. After amplification, the PCR products were analyzed by electrophoresis in a 4% agarose gel stained with ethidium bromide and optically visualized by ultraviolet (UV) transillumination. Specificity of the amplified fragments was confirmed by Southern blot hybridization with type-specific 32 Plabeled oligonucleotide probes: EBV type 1 5'-TCCAGCCACATG-TCCCCCCTCTACGCCCGACA-3', and EBV type 2 5'-AACGTC-AACCTGTCCACAACCCTCGCCAGGAG-3'.
HIV-and HD-Related Features
All patients had evidence of HIV infection, as determined by the presence of HIV antibodies by the enzyme-linked immunosorbent assay (ELISA) and confirmation by Western blot technique. Additionally, HIV features related to immunologic abnormalities and opportunistic infections (OI) were analyzed. The criteria used to diagnose persistent generalized lymphoadenopathy (PGL) and AIDS were those established by the Centers for Disease Control (CDC).4o All patients were evaluated for the extent of HD at the time of diagnosis by physical examination, complete blood cell count, blood chemistry, chest radiography, computed tomography of the abdomen, bone marrow aspirate, and biopsy. The staging system according to the Ann Arbor classification was adopted.
Treatments Used, Response and Survival Criteria
Most patients were treated with conventional chemotherapy regimens, ie, mechlorethamine, vincristine, procarbazine, and prednisone (MOPP), 4 and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) 4 chosen at the single institutions where these patients were observed. Since March 1989, 26 patients have been included in a prospective evaluation of concomitant chemotherapy and zidovudine. The chemotherapy regimen was a modification of EBVP, 43 ie, epirubicin 70 mg/m 2 intravenously (IV) on day 1, bleomycin 10 mg/ m 2 IV on day 1, vinblastine 6 mg/m' IV on day 1, and prednisone 40 mg/m' orally on days I to 5 every 3 weeks. In the first 17 treated patients," prednisone was omitted, but from January 1993 it was included. Zidovudine 500 mg/day orally was given concomitantly.
Complete response (CR) was defined as a complete disappearance of all measurable disease lasting at least 4 weeks. Partial response (PR) was defined as more than 50% reduction in the sum of the products of the cross-sectional diameters of all known lesions. No response (NR) was defined as less than a PR. as an increase of the area of measurable disease, or as a development of new lesions. Response duration was computed from the start of treatment to the date of documented disease recurrence or progression. Survival was TIRELW ET AL calculated from the day of diagnosis to death or to the time of last patient contact. Survival curves were extimated by the Kaplan-Meier method, 4 5 and distributional comparisons were made with the method of Mantel." Significant tests for proportions were computed by means of the X 2 tests.
Because of the fact that the majority of patients were IV drug users (IVDUs), frequent changes of address and of treating physicians and other economic and logistic problems were present; therefore, complete information was not available for all cases.
RESULTS
General Characteristics
From November 1986 to March 1994, data was collected on 114 patients with HD and HIV infection, whose clinicopathologic findings are listed in Table 1 . One hundred three patients (90%) were males, and the median age was 29 years (range, 19 to 57 years). In regard to the risk group, the majority (79%) of patients were IVDUs, in accordance with the epidemiology of the HIV infection in Italy. At the time of diagnosis of HD, 17 of 102 (17%) of the patients already had a diagnosis of AIDS, 29 of 102 (28%) had PGL, 22 of 102 (22%) had AIDS-related complex (ARC), and 34 of 102 (33%) were asymptomatic for HIV infection. The median CD4+ cell count at the time of diagnosis of HD was 275/4uL (range, 9 to 1,100/1L), and 56 of 104 patients (54%) had a CD4+ cell count less than 400/pL. No statistically significant differences (P > .10) emerged in the mean number of CD4+ cells at the time of HD diagnosis according to the histologic subtype of HD. Twenty-eight of 93 patients (30%) had active OI (Cl or C2 according to the CDC classification) at onset of HD.
The 104 patients without HIV infection who were used as a control group consisted of 56% males and 44% females, the median age being 38 years (range, 15 to 76 years).
Pathologic and Virologic Findings
In regard to the histologic subtypes, lymphocyte predominance (LP) was observed in 4 of 107 patients (4%), (Fig 1) . The remaining seven cases were not classified. The frequency of the distribution of HD subtypes in HIV-infected patients was compared with that observed in the control series of 104 patients without HIV infection who were histologically diagnosed at our institution. Overall, we found a frequency of MC plus LD in an HIV setting of 66% compared with 29% of HIV-negative patients (P < .001). In contrast, LP plus NS subtypes were more frequent in the HIV-negative group (34% v 71%; P < .001).
The immunogenotypical characterization of 10 HD cases from HIV-seropositive patients, performed by Southern blotting analysis of the configuration of genes encoding for Ig heavy and light chains and T-cell receptor beta chain, revealed no evidence of B-or T-cell clonal expansions. Additionally, the use of a more sensitive analitical method constituted by two different PCR amplification protocols for the detection of IgH gene rearrangements (VDJ PCR) failed to reveal the presence of a B-cell clonality in these cases. Similar findings were obtained in a control group of 20 HD cases without HIV infection. The association with EBV was investigated by in situ hybridization with EBV RNA probes, immunostaining for LMP-I expression (Fig 1) , and Southern blotting for the detection of monoclonal EBV genomes in the cases for which frozen material was available. Such a combined approach revealed that 14 (78%) of the 18 HD cases with HIV infection investigated were EBV-associated. The analysis of the configuration of the EBV genome termini revealed the presence of monoclonal EBV genomes in eight of the 10 (80%) HIV-associated cases investigated (Fig 2) . In contrast, only 12 of 44 (38%) HIV-unrelated HD cases were shown to carry monoclonal expansions of EBV-infected cells. In particular, in all HIV-associated EBV-positive HD cases analyzed, a single monoclonal EBV episome was observed (Fig 2) , indicating that the putative neoplastic cell population of these cases was derived from a single EBV-infected cell. Additionally, Southern blot analysis allowed the detection of the same monoclonal EBV episome in multiple metachronous lesions of the disease in two patients (Fig 2) . The frequency of LMP-1 expression in our series of HDs from HIVinfected patients (78%) was significantly higher than that observed in our control group of HIV-unrelated HD cases (27 of 104, 25%; P < .001; Table 2 ). We have also investigated the possible involvement of different EBV subtypes in the development of HD in the HIV setting.
For this purpose, 11 EBV-positive HDs from HIV-infected patients have been characterized for the presence of either type 1 or type 2 EBV infection by using a PCRbased amplification of EBNA-2 sequences, which are characteristically different in the two EBV subtypes. Type 2 EBV was detected in six of 11 cases (two cases showed a concomitant type 1 positivity), whereas only one of 26 EBV-positive HD cases from HIV-seronegative patients was shown to carry type 2 EBV (data not shown).
Clinical Findings
Seven of 108 (6%) patients had stage I, 14 of 108 (13%) had stage II, 31 of 108 (29%) had stage III, and 56 of 108 (52%) had stage IV HD. Seventy-eight of 101 patients (77%) had B symptoms at onset of HD (Table  1) . On the other hand, of 104 HIV-negative patients, stages III and IV HD was observed in 29% and 15% of cases, respectively, while B symptoms were present in 35% of patients. The overall extranodal involvement was 63%, significantly higher than in the control group of HIV-negative patients (29%). Bone marrow, spleen, and liver were involved in 39%, 35% and 22% of cases, respectively. Mediastinal involvement was present in only 21 of 91 (23%) patients whose involved nodal areas were specified. We observed a statistically significant lower rate of mediastinal involvement in patients with HD and HIV infection compared with 104 HIV-negative patients (23% v 58%; P < .001). This difference was also true in patients with NS subtype (27% v 80%, respectively; P < .001). The frequency of mediastinal involvement in patients with MC histology was not different in the two groups (23% v 21%; P = .81).
Twelve of 106 patients with HIV infection were not treated for their HD because of a poor performance status and/or short life expectancy and in two cases because the diagnosis was made postmortem; seven of 106 (7%) patients received radiotherapy (RT) alone, and 87 of 106 (82%) received chemotherapy (nitrogen mustard, vincristine, procarbazine, and prednisone [MOPP], adriamycin, bleomycin, vinblastine, and dacarbazine [ABVD], MOPP-ABVD, epirubicin, bleomycin, vinblastine, and prednisone [EBVP]) alone or followed by RT. Zidovudine and Pneumocystis carinii pneumonia (PCP) prophylaxis were never systematically used in patients treated with MOPP, ABVD, or MOPP-ABVD because these treatments procedures were not available (zidovudine) or were not developed (PCP prophylaxis) at that time, whereas they were concomitantly used with EBVP. In the first group of patients treated with the EBVP regimen, PCP prophylaxis consisted of inhaled pentamidine isethionate (300 mg once a month) only for patients who had a CD4+ cell count 2 200/jiL," whereas in the second group of patients, after co-trimoxazole was found effective, it was given to all patients (160/800 mg twice a day) regardless of CD4+ cell count. Twenty-three patients received MOPP with or without RT, seven patients received ABVD with or without RT, 23 patients received MOPP alternating or followed by ABVD with or without RT, 26 patients received EBVP, and eight patients were treated with several different regimens. After MOPP with or without RT, CR was observed in seven of 17 (41%) patients, whereas the other 10 (59%) achieved a PR. Eleven of 15 assessable patients (73%) developed OI (four PCP, three esophageal candidiasis, three cerebral toxoplasmosis, and one extrapulmonary tuberculosis) during treatment or follow-up (median follow-up, 10 months). Of seven patients treated with ABVD with or without RT, only three were assessable for response (one CR and two PR), whereas only four were assessable for the development of infections (two OI: one esophageal candidiasis and one cytomegalovirus retinitis). After MOPP alternated or followed by ABVD regimen with or without RT, CR was observed in 13 of 19 patients (68%), whereas the other six patients achieved a PR. With a median follow-up of 12 months, five of 13 (38%) patients developed OI (two cryptococcal meningitis, one cerebral toxoplasmosis, one esophageal candidiasis, and one cytomegalovirus retinitis). Overall, among 32 assessable patients treated with the previously mentioned standard CT regimens and without PCP prophylaxis, PCP was detected in four (12%) patients. Of the 26 patients treated with EBVP, CR was observed in 15 of 26 (58%) patients and PR in seven (27%). With a median follow-up of 10 months, four of 25 (16%) assessable patients developed OI (one PCP, two extrapulmonary tuberculosis, and one cytomegalovirus retinitis). Therefore, PCP was observed only in one (6%) of 17 patients receiving PCP prophylaxis, and this rate was lower than that found in patients treated with standard CT regimens and not receiving PCP prophylaxis (6% v 12%). Table 3 lists these data. Toxicity was evaluated in patients treated in the prospective study with EBVP and zidovudine. The most common side effect was bone marrow suppression. Overall, in five patients, we observed grade III leukopenia, and in one, grade III thrombocytopenia; in four patients, we observed grade IV leukopenia, and in no patient, grade IV thrombocytopenia. Nonhematologic toxicity was mild, and no cardiac toxicity was observed. Sixty-nine of 114 (60%) patients died. Twenty-one of 60 assessable patients (35%) died of OI, 20 of 60 (33%) of HD, seven of 60 (12%) of HD plus OI, two died of non-OI, three died of liver failure, two died of septic shock, two died of wasting syndrome, one died of treatment-related bone marrow toxicity, one of overdose, and one of pericarditis. The median survival of 114 patients was 15 months (range, 1 to 79 months; Fig 3, top left) . The median survival of patients achieving a CR was 58 months, whereas median survival of the remaining patients was 11 months (P < .001; Fig 3, bottom left) . In the first group of patients, some can be considered cured of their HD in that they live without evidence of disease after 7 years, although the majority of CR patients are still at risk of relapse. Patients with CD4+ cell count 2 250/ML at diagnosis of HD had a median survival of 11 months, whereas patients who had a CD4+ cell count higher than 250/,L had a median survival of 38 months (P < .002; Fig 3, top right) . The median survival of patients with or without a diagnosis of AIDS at onset of HD was 7 and 20 months, respectively (P < .001; Fig  3, bottom right) .
DISCUSSION
Although conclusive studies regarding the increased frequency of HD in an AIDS setting are presently lacking, HD in patients with HIV infection is associated with unfavorable histology, advanced stage, and poor therapeutic outcome, along with high incidence of associated OIs.10.12-21 Because of the relatively high incidence of HD in the age group most at risk for HIV infection, the relationship between HD and HIV infection is still difficult to evaluate. However, the majority of patients in our series (79%) were IVDUs, more than expected, taking The reason for such a correlation is still a matter of discussion, although it has been hypothesized that transmission of blood-borne infectious agents may be implied in the pathogenesis of HD in IVDUs with HIV infection.
• '" Our study reveals, in patients with HD and HIV infection, in comparison with our monoinstitutional series of 104 HIV-negative patients with HD, a younger median age (29 v 38 years), a prevalence of males (90% v 56%), a higher percentage of stage IV disease (52% v 15%), B symptoms (77% v 35%), and extranodal disease (63% v 29%) at presentation. We also observed, in accordance with other published series,1' 0 12.1 4 '16 a higher rate (77% v 42%) of patients with HD without mediastinal involvement as a specific feature of the HIV setting. Moreover, we have detected a significant difference in the distribution of HD histologic subtypes in HIV-infected patients compared with HD in the general population. We found that in HIV-infected patients, the frequency of the two main subtypes, ie, NS and MC, is reversed. These findings are not indicative of a significant association between HIV infection and HD, but they support the hypothesis that HD in HIV-infected patients may have features distinctive from those observed in the general population. It seems conceivable that HD of the MC or LD subtypes in HIV-infected individuals, with atypical pattern of clinical presentation and advanced-stage disease, may be considered an AIDS-related malignancy, irrespective and in absence of the numerically increase of such neoplasia. However, in this regard, Hessol et al 5 indicated an excessive incidence of HD in HIV-infected homosexual men in San Francisco, and Reynolds et al 7 showed the same in their registry linkage study. With respect to immunogenotypical characteristics, HIV-associated HDs are similar to those of HIV-seronegative patients because in both groups, no evidence of Bor T-cell clonal expansion was obtained by Southern blot analysis. That the search for B-cell clonality by a sensitive VDJ PCR was also repeatedly negative in these cases indicates that either Reed-Sternberg cells and their precursors do not rearrange IgH genes or, if they undergo functional IgH gene rearrangements, these cells are polyclonal or, alternatively, clonal but representing less than 1% of the total cell population. Our virologic findings derived from the combined use of in situ hybridization, immunohistochemical detection of EBV-encoded LMP-1, and Southern blot analysis indicate that HIV-related HD cases are more closely associated with EBV than those from the general population. In particular, a significantly higher frequency of cases with Reed-Sternberg cells that are positive for LMP-I expression was observed among HDs from HIV-infected patients with respect to those in HIVseronegative individuals (78% v 25%). However, it is worth noting that such a marked difference in the incidence of EBV association may be, in part, because of the high frequency of the MC and LD subtypes (13 of 18) in the subset of the HDs from HIV-infected patients studied for EBV. It is known that EBV association is stronger with the aggressive MC and LD subtypes of HD than with the other subtypes. 4 7 The possible etiologic role of EBV in the large majority of HIV-related HD cases is also supported by the detection of monoclonal EBV genomes in all of the EBV-positive cases analyzed. In fact, this finding indicates that in these cases, a monoclonal expansion of EBV-carrying cells is present, which probably is responsible for the induction and the persistence of the disease in an active state. Moreover, the demonstration that the same EBV-infected clone is present in multiple metachronous localization of HD from HIV-seropositive patients provides further evidence supporting the causal involvement of EBV in the pathogenesis of HD. Recently, two types of EBV, which show differences in the sequences encoding for EBNA-2, -3, -4, and -6, have been described. Type 2 EBV, which was shown to have a reduced transforming potential with respect to type 1 EBV, is rarely detected in peripheral-blood lymphocytes (PBLs) from healthy western individuals. In contrast, immunosuppressed patients, including those who are HIVinfected, frequently carry type 2 EBV in their PBLs. Our characterization of EBV subtypes showed that type 1 and type 2 EBV were almost equivalently distributed in HD cases from HIV-infected patients. These findings indicate that in the setting of HIV infection, type 2 EBV also may be pathogenetically involved in the induction of HD, as previously reported for HIV-associated non-Hodgkin's lymphomas."
In regard to the treatments used, it seems that the addition of antiretroviral therapy and PCP prophylaxis to the EBVP regimen was feasible, resulting in a low occurrence of OI, in particular of PCP.
The overall median survival of our group was 15 months, with a significant increase in the median survival observed in patients with a median CD4+ cell count higher than 250/uL, in patients without defined AIDS at onset of HD, and in patients who received a treatment and obtained a CR as well. The importance on survival of the same prognostic factors was also demonstrated in other studies,'
2 " and median overall survival in patients of the present experience was not different from that oband live for a long time without relapse. On the other served in previous reports. 10°1 2.14-18s20 hand, there are patients dying of causes related to Interestingly, in this large series of HIV-infected HD underlying HIV infection, but without evidence patients, some can be cured of their neoplastic disease of HD.
